Lefkothea Papadopoulou

Prof. Lefkothea Papadopoulou

orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1999 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
LPLefkothea Papadopoulou
Lefkothea Papadopoulou
CSCarolyn M. Sue
Carolyn M. Sue
MDMercy M. Davidson
Mercy M. Davidson
KTKurenai Tanji
Kurenai Tanji
INIchizo Nishino
Ichizo Nishino
ESEric A. Schon
Eric A. Schon

31 May 2018 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
AMAndroulla N. Miliotou
Androulla N. Miliotou
LPLefkothea Papadopoulou
Lefkothea Papadopoulou
Background: Cancer is one of the leading causes of death worldwide. Over the years, a number of conventional cytotoxic approaches for neoplastic diseases has been developed. However, due to their limited effectiveness in accordance with the heterogeneity of cancer cells, there is a constant search for therapeutic approaches with improved outcome, such as immunotherapy that utilizes and enhances the normal capacity of the patient’s immune system. Methods: Chimeric Antigen Receptor (CAR) T-cell therapy involves genetic modification of patient’s autologous T-cells to express a CAR specific for a tumor antigen, following by ex vivo cell expansion and re-infusion back to the patient. CARs are fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signaling domains. This T-cell genetic modification may occur either via viral-based gene transfer methods or nonviral methods, such as DNA-based transposons, CRISPR/Cas9 technology or direct transfer of in vitro transcribed-mRNA by electroporation. Results: Clinical trials have shown very promising results in end-stage patients with a full recovery of up to 92% in Acute Lymphocytic Leukemia. Despite such results in hematological cancers, the effective translation of CAR T-cell therapy to solid tumors and the corresponding clinical experience is limited due to therapeutic barriers, like CAR T-cell expansion, persistence, trafficking, and fate within tumors. Conclusion: In this review, the basic design of CARs, the main genetic modification strategies, the safety matters as well as the initial clinical experience with CAR T-cells are described.

1 August 2006 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
ATAsterios Tsiftsoglou
Asterios Tsiftsoglou
ATAthina I. Tsamadou
Athina I. Tsamadou
LPLefkothea Papadopoulou
Lefkothea Papadopoulou

1 March 1999 in Biochemical Pharmacology
Verified
Journal Article
Closed access
LPLefkothea Papadopoulou
Lefkothea Papadopoulou
GTGeorge Theophilidis
George Theophilidis
GTGeorge N Thomopoulos
George N Thomopoulos
ATAsterios Tsiftsoglou
Asterios Tsiftsoglou

1 October 1997 in The American Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
GMGiovanni Manfredi
Giovanni Manfredi
DTDominic Thyagarajan
Dominic Thyagarajan
LPLefkothea Papadopoulou
Lefkothea Papadopoulou
Francesco PallottiFrancesco Pallotti
Francesco Pallotti
ESEric A. Schon
Eric A. Schon
Inheritance of animal mtDNA is almost exclusively maternal, most likely because sperm-derived mitochondria are actively eliminated from the ovum, either at or soon after fertilization. How such elimination occurs is currently unknown. We asked whether similar behavior could be detected in somatic cells, by following the fate of mitochondria and mtDNAs after entry of human sperm into transformed cells containing mitochondria but lacking endogenous mtDNAs (rho0 cells). We found that a high proportion (10%-20%) of cells contained functioning sperm mitochondria soon after sperm entry. However, under selective conditions permitting only the survival of cells harboring functional mtDNAs, only approximately 1/10(5) cells containing sperm mitochondria survived and proliferated. These data imply that mitochondria in sperm can enter somatic cells relatively easily, but they also suggest that mechanisms exist to eliminate sperm-derived mtDNA from somatic cells, mechanisms perhaps similar to those presumed to operate in the fertilized oocyte.

1 July 2016 in Journal of Inorganic Biochemistry
Verified
Journal Article
Closed access
TKTheocharis E. Kydonaki
Theocharis E. Kydonaki
ETEvangelos Tsoukas
Evangelos Tsoukas
Filipa MendesFilipa Mendes
Filipa Mendes
AHAntonios G. Hatzidimitriou
Antonios G. Hatzidimitriou
António PauloAntónio Paulo
António Paulo
GPGeorge Psomas
George Psomas